NCT01267955View on ClinicalTrials.gov

Vismodegib in Treating Patients With Advanced Chondrosarcomas

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 21, 2010

Primary Completion Date

June 30, 2018

Study Completion Date

July 21, 2026

Conditions
Clear Cell ChondrosarcomaDedifferentiated ChondrosarcomaLocally Advanced ChondrosarcomaMesenchymal ChondrosarcomaMetastatic ChondrosarcomaPrimary Central ChondrosarcomaUnresectable Primary Central Chondrosarcoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacogenomic Study

Correlative studies

DRUG

Vismodegib

Given PO

Trial Locations (6)

13385

Hopital De La Timone, Marseille

33076

Institut Bergonie Cancer Center, Bordeaux

59020

Centre Oscar Lambert, Lille

69373

Centre Leon Berard, Lyon

75005

Institut Curie Paris, Paris

94805

Gustave Roussy, Villejuif

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH